Related Experiment Video

Updated: Mar 11, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Triptolide inhibits tumor growth by induction of cellular senescence

Ruidong Li1, Xiaofei Zhang1, Xiaoying Tian2

  • 1Department of General Surgery and Liver Transplant Center, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.

Oncology Reports
|November 24, 2016
PubMed

Insights

Triptolide (TPL) inhibits HepG2 tumor growth by inducing cellular senescence. This occurs through simultaneous regulation of the AKT and human telomerase reverse transcriptase (hTERT) pathways, offering a novel anticancer strategy.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cellular senescence is a key mechanism in cancer prevention.
  • Triptolide (TPL) exhibits anticancer properties, but its role in senescence-associated antitumor effects is underexplored.

Purpose of the Study:

  • To investigate the effect and mechanism of TPL on tumor growth and cellular senescence in HepG2 cells.
  • To elucidate the molecular pathways involved in TPL-induced senescence.

Main Methods:

  • In vitro and in vivo experiments using HepG2 cells.
  • Analysis of cell proliferation, growth, and cell cycle arrest (G0/G1 phase).
  • Investigation of the roles of the AKT and human telomerase reverse transcriptase (hTERT) signaling pathways.

Main Results:

  • TPL significantly inhibited HepG2 cell proliferation and tumor growth.
  • TPL treatment accelerated cellular senescence and induced G0/G1 phase arrest.
  • TPL modulated the AKT and hTERT signaling pathways to promote senescence.

Conclusions:

  • TPL induces HepG2 cell senescence through simultaneous activation of the AKT and hTERT pathways.
  • TPL-driven cellular senescence presents a promising therapeutic strategy for anticancer drug development.

More Related Videos

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.6K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

598

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.5K
Replicative Cell Senescence02:15

Replicative Cell Senescence

3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K